AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01139216
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 4 weeks.
Trial: NCT03999008
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apple Sauce 5 mL+ 1 mL saline
Trial: NCT02532855
Drug: Sulfonylurea
RxNorm normalized name: Sulfonylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This medication is a standard-of-care medication and is administered in an open-label fashion. The dose of the sulfonylurea agent will be required to be at least 50% of maximum labeled dose, consistent with near maximum efficacy of the sulfonylurea agent.
Trial: NCT02285491
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of saline will be injected as a placebo and the investigator and the patient and the data assessor are all blinded to what the patients received.
Trial: NCT03044873
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin on Day 1. BMS 986165 on Days 5-8 and Days 10-12. On Day 9, BMS 986165 coadministered with an oral dose of rosuvastatin.
Trial: NCT02668367
Drug: BTA-C585 oral capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BTA-C585; Multiple ascending doses from 100 mg to 600 mg
Trial: NCT01811160
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A capsule of melatonin was administered nightly (20:00hrs).
Trial: NCT01811160
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules were administered at 20:00hrs for eight weeks
Trial: NCT00004162
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02751424
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A clear and colorless solution containing 0.9% sodium chloride. It will administered as IV infusion over 1 hour.
Trial: NCT03206749
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received placebo matched to VX-150 and HB/APAP for 2 days.
Trial: NCT01884844
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03081897
Drug: SPRANC Control group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anaesthesia with Propofol (2mg/kgKG) and Remifentanil (0,1-0,4 µg/kg/min); additional regional Patient Control Group (no Intervention planned), general anaesthesia with Propofol (2mg/kgKG) and Remifentanil (0,1-0,4 µg/kg/min); unilateral neck dissection.
Trial: NCT03170739
Drug: Dopamine
RxNorm normalized name: Dopamine
DrugBank: Dopamine (DB00988)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dopamine given during surgery.
Trial: NCT03820258
Drug: SOF/VEL/VOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered once daily with food.
Trial: NCT02542462
Drug: Rotarix®,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of licensed rotavirus vaccine given alone
Trial: NCT02542462
Drug: Rotarix®, with other routine vaccines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of licensed rotavirus vaccine given with other routine vaccines
Trial: NCT02542462
Drug: RotaTeq®,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of licensed rotavirus vaccine given alone
Trial: NCT02542462
Drug: RotaTeq®, with other routine vaccines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of licensed rotavirus vaccine given with other routine vaccines
Trial: NCT01676285
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01690780
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 10 mg/kg (max 600 mg) every 6 hours as needed for pain (maximum 4 doses) for 24 hours following discharge from the emergency department
Trial: NCT05983289
Drug: HSK7653
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSK7653 tablets in six doses beginning at 5 mg and rising to 150 mg
Trial: NCT05983289
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tables in six doses beginning at 5 mg and rising to 150 mg
Trial: NCT02082678
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive ingredient matching the active medication in appearance
Trial: NCT01531790
Drug: Centrum
RxNorm normalized name: Centrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet/day
Trial: NCT02784262
Drug: botox injection Multiguide
RxNorm normalized name: onabotulinumtoxinA Injection [Botox]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: botox injection under CT/MR navigation and with the navigation tool MultiGuide
Trial: NCT03090113
Drug: Shuxuetong Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous drip
Trial: NCT03090113
Drug: Placebo Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous drip
Trial: NCT00001830
Drug: Th2 cells in allo HSCTT
RxNorm normalized name: allo-2-hydroxycitric acid
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00001830
Drug: Th2 Cells
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02349178
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Days 1-5 receive Cyclophosphamide 300 mg/m2 IV as a 30-60 minute infusion
Trial: NCT01572662
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5 mg/m2 by vein on Days 1, 3, 6 and 11 post transplant.
Trial: NCT03396380
Drug: Vitamin D with calcium and clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. Vitamin D ( ossofortin®, EVA PHARMA) 10000 IU twice weekly and calcium (calciprex®, Marcyrl Pharmaceutical Industries ) 1250 mg twice daily which provide elemental calcium 500 mg/tablet for one month before induction of ovulation and both will be continued during the 3 induction cycles in the same regimen.~2. Induction of ovulation by clomiphene citrate (Clomid®, Aventis) 50 mg tablet twice daily 12 hours apart (total dose 100 mg daily) starting from the third day of menstrual cycle and for five days .
Trial: NCT03396380
Drug: Placebo Oral Tablet with calcium and clomiphene citrate
RxNorm normalized name: clomiphene Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. The placebo tablet twice weekly and calcium (calciprex®, Marcyrl Pharmaceutical Industries ) 1250 mg twice daily which provide elemental calcium 500 mg/tablet for one month before induction of ovulation and both will be continued during the 3 induction cycles in the same regimen.~2. induction of ovulation by clomiphene citrate (Clomid®, Aventis) 50 mg tablet twice daily 12 hours apart (total dose 100 mg daily)starting from the 3rd day of menstrual cycle and for five days
Trial: NCT00210639
Drug: No intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an observational study. Participants rceiving dosing regimen from the respective Phase 3 levofloxacin clinical studies will be observed in this study.
Trial: NCT03508921
Drug: Periprocedural Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One the day of injection, after eligibility is determined and consent obtained, research staff will refer to the randomization list to determine to which arm the patient is randomized. Patients randomized to the Procedural Antibiotics Only arm will receive a single dose of trimethoprim/sulfamethoxazole (800/160mg) peri-procedurally at the time of the first injection.
Trial: NCT03508921
Drug: Extended Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to the Extended Antibiotics arm will receive one dose of trimethoprim/sulfamethoxazole peri-procedurally and additionally be prescribed trimethoprim/sulfamethoxazole twice daily for three days. Patients who are allergic will receive amoxicillin/clavulanic acid (875/125mg) twice daily for three days. If allergic to both of the above antibiotics, patients will receive 100mg nitrofurantoin BID for three days.~For their second injection, they will receive peri-procedural antibiotics only.
Trial: NCT03520972
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 eligible patients will be included in this group
Trial: NCT01860638
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered via IV infusion, in a formulation matched to bevacizumab, Q2W after randomization.
Trial: NCT03899454
Drug: Placebo Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Control
Trial: NCT01860638
Drug: SOC Agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The choice of SOC agent will be at the discretion of investigator. The SOC agent will be administered during third-line treatment and subsequent lines, as per standard practice.
Trial: NCT01756885
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On Day 85, participants randomized to standard therapy will be given placebo pills (resembling the 1.0mg pills),
Trial: NCT00182260
Drug: Proton Pump Inhibitors
RxNorm normalized name: Proton pump inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00897676
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (0.9% NaCl)
Trial: NCT02946424
Drug: Placebo Oral Capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 month course of daily placebo
Trial: NCT02946424
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 month course of daily simvastatin
Trial: NCT02317562
Drug: I10E
RxNorm normalized name: SET,INFUSION ACCU-CHEK ULTRAFLEX-I10-110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who met all eligibility criteria will receive 0.5 g/kg of IMP every 3 weeks during 45 weeks.
Trial: NCT03551743
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04502589
Drug: Disulfiram
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Disulfiram will be kept at 250mg daily
Trial: NCT01522846
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparinized flush solution contained heparin concentration of 2 unit/ml and continuous flow of the flush solution was 5 ml/h at 300 mmHg.
Trial: NCT01936103
Drug: standard group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard statin treatment:Atorvastatin statins 20mg / night .
Trial: NCT01936103
Drug: intensive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intensive statin treatment： Admission atorvastatin statins the 80mg, after surgery，atorvastatin 40mg / night，and until 30 days after the operation
Trial: NCT01009476
Drug: Nootropics (ginkgo biloba, nicergoline, piracetam, or others)
RxNorm normalized name: Other psychostimulants and nootropics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic measures were not predefined in the protocol but remained at the discretion of the treating physician. The treatment regimen of nootropics was to be in accordance with the recommendations given in the relevant summary of product characteristics.
Trial: NCT00577655
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo HFA MDI four times a day (q.i.d) for 21 days.
Trial: NCT00577655
Drug: Proventil® HFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proventil® HFA (albuterol sulfate) Inhalation Aerosol (Key Pharmaceuticals) was used as rescue medication in this study. The rescue medication was over-labeled with instructions for emergency use in which subjects were instructed to self-administer up to two puffs every 20 minutes to a maximum of six puffs for any given episode while attempting to seek medical assistance.
Trial: NCT00945490
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intraprostatic injection of placebo
Trial: NCT00428597
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match sunitinib taken daily (oral) on the same schedule as active agent below.
Trial: NCT03436615
Drug: SB206 4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily
Trial: NCT03436615
Drug: SB206 8%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily
Trial: NCT03436615
Drug: SB206 12%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once or twice daily
Trial: NCT03436615
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once or twice daily
Trial: NCT00817011
Drug: SSRI treated group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant administration of SSRI class for 6 weeks under therapeutic dose
Trial: NCT00817011
Drug: non-SSRI treated group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant administration of non-SSRI class for 6 weeks under therapeutic dose
Trial: NCT04432558
Drug: Tramadol, paracetamol, diclofenac sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The analgesic consumption of the patients will be recorded
Trial: NCT02107469
Drug: Sida cordifolia roots
RxNorm normalized name: Rubia cordifolia root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sida cordifolia roots, crude drug (coarse powder) a plant product 7g (packages prepared) are soaked in 112ml water (measurement cup provided) for 12 hours and then boiled until the level is reduced to 1/4 of hight. Fluid is filtered an drunk after cooling down to room temperature - orally 2 times a day before breakfast and dinner
Trial: NCT02107469
Drug: Phyllanthus niruri
RxNorm normalized name: PHYLLANTHUS NIRURI WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phyllanthus niruri (whole plant) fine powder 3g three times a day with warm water before meals taken orally.
Trial: NCT02107469
Drug: Sida cordifolia roots extract
RxNorm normalized name: Rubia cordifolia root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gelatine capsule with 300mg Sida cordifolia roots spraydry extract 12:1 concentrated normalized to alkaloids (alcoholic/aqueous extract) - 2 capsules taken orally 2 times a day with warm water before meal
Trial: NCT02107469
Drug: Phyllanthus niruri extract
RxNorm normalized name: Phyllanthus niruri top extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gelatine capsule with 300mg Phyllanthus niruri spray dry extract 5:1 concentrated normalized to bitters (alcohol/aqueous extract) - 2 capsules taken orally 3 times a day with warm water before meal
Trial: NCT03487939
Drug: FOLFOXIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IRINOTECAN 150 mg/m\^2 IV over 1-h, day 1 + OXALIPLATIN 85 mg/m\^2 IV over 2-h, day 1 + L-LEUCOVORIN 200 mg/m\^2 IV over 2-h, day 1 + 5-FLUOROURACIL 2800 mg/m\^2 IV 48-h continuous infusion, starting on day 1 administered every two weeks for 4 cycles (2 months).
Trial: NCT01370863
Drug: SPD557
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg tablet t.i.d. for 4 weeks on top of stable PPI treatment
Trial: NCT01370863
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo tablet t.i.d. for 4 weeks on top of stable PPI treatment
Trial: NCT00330473
Drug: Human Insulin Inhalation Powder
RxNorm normalized name: insulin, regular, human Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patient specific dose, inhaled, before meals, 9 months ( if patient chooses Human Insulin Inhalation Powder option)
Trial: NCT03341169
Drug: N(2)-L-Alanine L-Glutamine dipeptide
RxNorm normalized name: N-ethyl-L-glutamine
DrugBank: Theanine (DB12444)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: :Intravenous infusion of N (2) -L-alanyl-L-glutamine(mixed with normal saline, ratio 1:1) at the dose of 0.25g/kg(body weight) for 8 hours before induction of anesthesia(rate=2.5\*weight/8 ml/h) and administration another 0.25g/kg(body weight) of N (2) -L-alanyl-L-glutamine(mixed with 8.5% amino acid solution, ratio 1:5) into the central vein for 10 hours after induction of anesthesia(rate=0.75\*weight ml/h)
Trial: NCT03341169
Drug: placebo (0.9% NaCl (normal saline))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 0.9% NaCl for 8 hours before induction of anesthesia(rate=2.5\*weight/8 ml/h) and administration 0.9% NaCl into the central vein for 10 hours after induction of anesthesia(rate=0.75\*weight ml/h)
Trial: NCT01441349
Drug: IP chemotherapy plus simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Cisplatin(30mg/m2)diluted into 150 ml of 0.9% NS for IV over 30 min on day 1 \&8~* Irinotecan( 65 mg/m2) diluted into 200ml of 5DW IV over 90 min on day 1\& 8.~* Every 21days.~* Simvastatin 40 mg per day orally D1of cycle 1
Trial: NCT01852799
Drug: PAD Followed by ASCT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Bortezomib, Bortezomib (1.3mg/m2, iv, on day 1, 4, 8, 11, of each 28 day cycle)~Drug: Adriamycin (Doxorubicin) /EPI, Adriamycin (Doxorubicin) (9 mg/m2, iv, on days 1-4 of each 28 day cycle) or EPI (15mg/m2, iv, on days 1-4 of each 28 day cycle)~Drug: Dexamethasone, Dexamethasone (20mg, iv, on days 1-4, 8-11of each 28 day cycle)~After received induction therapy, patients will proceed to receive ASCT based on the willing of the patients and the decision of the investigators.
Trial: NCT01959828
Drug: IK-3001
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02715687
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Will receive 30 days treatment with oral placebo of 200mg
Trial: NCT01943565
Drug: spinal anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine 0.75% 1.6 mL (12mg)
Trial: NCT03192397
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01583374
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identically matched placebo tablets were taken orally twice a day during the placebo controlled phase.
Trial: NCT01265524
Drug: CLP
RxNorm normalized name: Endopeptidase Clp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT01265524
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT00009945
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 pills PO daily
Trial: NCT02994147
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-only control study medication is the same formulation as active treatment without active ingredient
Trial: NCT01459380
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02606032
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: active comparator
Trial: NCT02606032
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: identical placebos to all antibiotics
Trial: NCT00314834
Drug: Intradialytic parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02071914
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo.
Trial: NCT01034995
Drug: SSR125543
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: capsule~Route of administration: oral
Trial: NCT01034995
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: capsule~Route of administration: oral
Trial: NCT05526313
Drug: Prilinostat Mesylate 1.2mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
Trial: NCT05526313
Drug: Prilinostat Mesylate 2.4mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
Trial: NCT05526313
Drug: Prilinostat Mesylate 4.0mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
Trial: NCT05526313
Drug: Prilinostat Mesylate 6.0mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
Trial: NCT05526313
Drug: Prilinostat Mesylate 8.4mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
Trial: NCT05526313
Drug: Prilinostat Mesylate 11.2mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
Trial: NCT05526313
Drug: Prilinostat Mesylate 15mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
Trial: NCT02227238
Drug: LPV/RTV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPV/RTV is supplied as the LPV/RTV oral tablet, which contains 200 mg of LPV and 50 mg of RTV
Trial: NCT01632306
Drug: LY2090314
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2090314 administered IV
Trial: NCT01632306
Drug: FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX administered IV